Market Access Buyer’s remorse: The UK’s VPAG With the ABPI wanting to change the scheme just over a year into its five-year term, it seems that they have buyer’s remorse.
News UK is becoming an 'outlier' for pharma, hitting investment UK pharma leaders have renewed calls for a rethink by the government on levies imposed on medicine sales, saying investment is already being hit.
Market Access NHS medicines spending in England in greater focus Leela Barham provides a perspective on the ABPI blog that covers understanding NHS medicines spending in England.
News Novo Nordisk returns to ABPI fold after two-year suspension Novo Nordisk has reached the end of its two-year suspension from the ABPI for breaches of its code of practice after making "sustained improvements."
News Pharma furious as UK Statutory Scheme rebate rate soars The UK pharma sector has reacted with consternation to the government's proposal to raise the Statutory Scheme rate to 32.2% in the last half of 2025.
News Lawrence Tallon will lead MHRA after June Raine retires Lawrence Tallon has been named head of the MHRA, effective 1st April, replacing Dame June Raine who is retiring.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
